Zentalis Pharmaceuticals, Inc.
ZNTL
$1.43
-$0.08-5.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 173.86% | -12.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 41.89% | -21.05% | |||
| Operating Income | 10.34% | 21.05% | |||
| Income Before Tax | -18.64% | 54.34% | |||
| Income Tax Expenses | -659.26% | -110.15% | |||
| Earnings from Continuing Operations | -18.21% | 54.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.21% | 54.51% | |||
| EBIT | 10.34% | 21.05% | |||
| EBITDA | 10.40% | 21.15% | |||
| EPS Basic | -17.96% | 54.55% | |||
| Normalized Basic EPS | -78.94% | 38.38% | |||
| EPS Diluted | -17.96% | 54.55% | |||
| Normalized Diluted EPS | -78.94% | 38.38% | |||
| Average Basic Shares Outstanding | 0.22% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.22% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||